ReP USP - Resultado da busca

Trabalho de evento-resumo periodico
Safety and feasibility of neoadjuvant combined chemotherapy of breast cancer with paclitaxel carried in a lipid nanoemulsion (LDE) associated with adriamycin and cyclophosphamide (2015)
Mattar, Andre; Ferreira, Luciana B.; Gebrim, Luiz H.; Hegg, Roberto; Maranhão, Raul Cavalcante
Source: Cancer Research. Conference titles: Annual CTRC-AACR San Antonio Breast Cancer Symposium. Unidades: FM, FCF
Subjects: QUIMIOTERAPIA, NEOPLASIAS MAMÁRIAS (QUIMIOTERAPIA), ANTINEOPLÁSICOS, NANOCOMPOSITOS, CO-TERAPIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MATTAR, Andre et al. Safety and feasibility of neoadjuvant combined chemotherapy of breast cancer with paclitaxel carried in a lipid nanoemulsion (LDE) associated with adriamycin and cyclophosphamide. Cancer Research. Baltimore: Faculdade de Medicina, Universidade de São Paulo. Disponível em: https://doi.org/10.1158/1538-7445.SABCS14-P6-02-06. Acesso em: 18 abr. 2024. , 2015
APA
Mattar, A., Ferreira, L. B., Gebrim, L. H., Hegg, R., & Maranhão, R. C. (2015). Safety and feasibility of neoadjuvant combined chemotherapy of breast cancer with paclitaxel carried in a lipid nanoemulsion (LDE) associated with adriamycin and cyclophosphamide. Cancer Research. Baltimore: Faculdade de Medicina, Universidade de São Paulo. doi:10.1158/1538-7445.SABCS14-P6-02-06
NLM
Mattar A, Ferreira LB, Gebrim LH, Hegg R, Maranhão RC. Safety and feasibility of neoadjuvant combined chemotherapy of breast cancer with paclitaxel carried in a lipid nanoemulsion (LDE) associated with adriamycin and cyclophosphamide [Internet]. Cancer Research. 2015 ; 75[citado 2024 abr. 18 ] Available from: https://doi.org/10.1158/1538-7445.SABCS14-P6-02-06
Vancouver
Mattar A, Ferreira LB, Gebrim LH, Hegg R, Maranhão RC. Safety and feasibility of neoadjuvant combined chemotherapy of breast cancer with paclitaxel carried in a lipid nanoemulsion (LDE) associated with adriamycin and cyclophosphamide [Internet]. Cancer Research. 2015 ; 75[citado 2024 abr. 18 ] Available from: https://doi.org/10.1158/1538-7445.SABCS14-P6-02-06
Trabalho de evento-resumo periodico
Reduction of HER2-associated lipogenic phenotype by docosahexaenoic acid (DHA) induces apoptosis in breast tumor cells harboring HER2 overexpression (2015)
Ravacci, Graziela R.; Brentani, M. Mitzi; Festuccia, William Tadeu Lara ; Tortelli, Tharcisio; Waitzberg, Angela F.; Waitzberg, Dan L.
Source: Cancer Research. Conference titles: Annual CTRC-AACR San Antonio Breast Cancer Symposium. Unidades: FM, ICB
Subjects: FENÓTIPOS, NEOPLASIAS MAMÁRIAS (GENÉTICA), APOPTROSE
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
RAVACCI, Graziela R. et al. Reduction of HER2-associated lipogenic phenotype by docosahexaenoic acid (DHA) induces apoptosis in breast tumor cells harboring HER2 overexpression. Cancer Research. Baltimore: Faculdade de Medicina, Universidade de São Paulo. Disponível em: https://doi.org/10.1158/1538-7445.SABCS14-P1-08-08. Acesso em: 18 abr. 2024. , 2015
APA
Ravacci, G. R., Brentani, M. M., Festuccia, W. T. L., Tortelli, T., Waitzberg, A. F., & Waitzberg, D. L. (2015). Reduction of HER2-associated lipogenic phenotype by docosahexaenoic acid (DHA) induces apoptosis in breast tumor cells harboring HER2 overexpression. Cancer Research. Baltimore: Faculdade de Medicina, Universidade de São Paulo. doi:10.1158/1538-7445.SABCS14-P1-08-08
NLM
Ravacci GR, Brentani MM, Festuccia WTL, Tortelli T, Waitzberg AF, Waitzberg DL. Reduction of HER2-associated lipogenic phenotype by docosahexaenoic acid (DHA) induces apoptosis in breast tumor cells harboring HER2 overexpression [Internet]. Cancer Research. 2015 ; 75[citado 2024 abr. 18 ] Available from: https://doi.org/10.1158/1538-7445.SABCS14-P1-08-08
Vancouver
Ravacci GR, Brentani MM, Festuccia WTL, Tortelli T, Waitzberg AF, Waitzberg DL. Reduction of HER2-associated lipogenic phenotype by docosahexaenoic acid (DHA) induces apoptosis in breast tumor cells harboring HER2 overexpression [Internet]. Cancer Research. 2015 ; 75[citado 2024 abr. 18 ] Available from: https://doi.org/10.1158/1538-7445.SABCS14-P1-08-08
Trabalho de evento-resumo periodico
Phase 3, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and paclitaxel as first-line therapy in women with HER2+ advanced breast cancer: BOLERO-1 (2015)
Hurvitz, Sara A.; Andre, Fabrice; Jiang, Zefei; Shao, Zhimin; Neciosup, Silvia P.; Mano, Max S.; Tseng, Ling-Min; Zhang, Qingyuan; Shen, Kunwei; Liu, Donggeng; Dreosti, Lydia M.; Feng, Jifeng; Burris, Howard A.; Toi, Masakazu; Buyse, Marc E.; Cabaribere, David; Lindsay, Mary-Ann; Kunz, Tiffany; Rao, Shantha; Pacaud, Lida B.; Taran, Tetiana; Slamon, Dennis
Source: Cancer Research. Conference titles: Annual CTRC-AACR San Antonio Breast Cancer Symposium. Unidade: FM
Subjects: PLACEBO, NEOPLASIAS MAMÁRIAS (FISIOPATOLOGIA), ESTUDOS RANDOMIZADOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
HURVITZ, Sara A. et al. Phase 3, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and paclitaxel as first-line therapy in women with HER2+ advanced breast cancer: BOLERO-1. Cancer Research. Baltimore: Faculdade de Medicina, Universidade de São Paulo. Disponível em: https://doi.org/10.1158/1538-7445.SABCS14-S6-01. Acesso em: 18 abr. 2024. , 2015
APA
Hurvitz, S. A., Andre, F., Jiang, Z., Shao, Z., Neciosup, S. P., Mano, M. S., et al. (2015). Phase 3, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and paclitaxel as first-line therapy in women with HER2+ advanced breast cancer: BOLERO-1. Cancer Research. Baltimore: Faculdade de Medicina, Universidade de São Paulo. doi:10.1158/1538-7445.SABCS14-S6-01
NLM
Hurvitz SA, Andre F, Jiang Z, Shao Z, Neciosup SP, Mano MS, Tseng L-M, Zhang Q, Shen K, Liu D, Dreosti LM, Feng J, Burris HA, Toi M, Buyse ME, Cabaribere D, Lindsay M-A, Kunz T, Rao S, Pacaud LB, Taran T, Slamon D. Phase 3, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and paclitaxel as first-line therapy in women with HER2+ advanced breast cancer: BOLERO-1 [Internet]. Cancer Research. 2015 ; 75[citado 2024 abr. 18 ] Available from: https://doi.org/10.1158/1538-7445.SABCS14-S6-01
Vancouver
Hurvitz SA, Andre F, Jiang Z, Shao Z, Neciosup SP, Mano MS, Tseng L-M, Zhang Q, Shen K, Liu D, Dreosti LM, Feng J, Burris HA, Toi M, Buyse ME, Cabaribere D, Lindsay M-A, Kunz T, Rao S, Pacaud LB, Taran T, Slamon D. Phase 3, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and paclitaxel as first-line therapy in women with HER2+ advanced breast cancer: BOLERO-1 [Internet]. Cancer Research. 2015 ; 75[citado 2024 abr. 18 ] Available from: https://doi.org/10.1158/1538-7445.SABCS14-S6-01
Trabalho de evento-resumo periodico
Metastatic lymph node fibroblasts maintain similar profile of stromal biomarkers registered in primary breast carcinomas (2015)
Mundim, Fiorita G. L.; Pasini, Fatima S.; Nonogaki, Suely; Soares, Fernando A.; Brentani, M. Mitzi; Logullo, Angela F.
Source: Cancer Research. Conference titles: Annual CTRC-AACR San Antonio Breast Cancer Symposium. Unidades: FM, FO
Subjects: BIOMARCADORES, NEOPLASIAS MAMÁRIAS (GENÉTICA), FIBROBLASTOS, PROGNÓSTICO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MUNDIM, Fiorita G. L. et al. Metastatic lymph node fibroblasts maintain similar profile of stromal biomarkers registered in primary breast carcinomas. Cancer Research. Baltimore: Faculdade de Medicina, Universidade de São Paulo. Disponível em: https://doi.org/10.1158/1538-7445.SABCS14-P4-04-24. Acesso em: 18 abr. 2024. , 2015
APA
Mundim, F. G. L., Pasini, F. S., Nonogaki, S., Soares, F. A., Brentani, M. M., & Logullo, A. F. (2015). Metastatic lymph node fibroblasts maintain similar profile of stromal biomarkers registered in primary breast carcinomas. Cancer Research. Baltimore: Faculdade de Medicina, Universidade de São Paulo. doi:10.1158/1538-7445.SABCS14-P4-04-24
NLM
Mundim FGL, Pasini FS, Nonogaki S, Soares FA, Brentani MM, Logullo AF. Metastatic lymph node fibroblasts maintain similar profile of stromal biomarkers registered in primary breast carcinomas [Internet]. Cancer Research. 2015 ; 75[citado 2024 abr. 18 ] Available from: https://doi.org/10.1158/1538-7445.SABCS14-P4-04-24
Vancouver
Mundim FGL, Pasini FS, Nonogaki S, Soares FA, Brentani MM, Logullo AF. Metastatic lymph node fibroblasts maintain similar profile of stromal biomarkers registered in primary breast carcinomas [Internet]. Cancer Research. 2015 ; 75[citado 2024 abr. 18 ] Available from: https://doi.org/10.1158/1538-7445.SABCS14-P4-04-24
Trabalho de evento-resumo periodico
Final efficacy results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer (2015)
Bell, Richard; Brown, Julia; Parmar, Mahesh; Toi, Mark; Suter, Thomas; Steger, Guenther; Pivot, Xavier; Mackey, John; Jackisch, Christian; Dent, Rebecca; Hall, Peter; Mecke, Almut; Morales, Leilani; Provencher, Louise; Staroslawska, Elzbieta; Hegg, Roberto; Vanlemmens, Laurence; Kirsch, Andreas; Schneeweiss, Andreas; Masuda, Norikazu; Overkamp, Friedrich; Cameron, David
Source: Cancer Research. Conference titles: Annual CTRC-AACR San Antonio Breast Cancer Symposium. Unidade: FM
Subjects: QUIMIOTERAPIA, NEOPLASIAS MAMÁRIAS (TERAPIA), ANTINEOPLÁSICOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BELL, Richard et al. Final efficacy results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer. Cancer Research. Baltimore: Faculdade de Medicina, Universidade de São Paulo. Disponível em: https://doi.org/10.1158/1538-7445.SABCS14-PD2-2. Acesso em: 18 abr. 2024. , 2015
APA
Bell, R., Brown, J., Parmar, M., Toi, M., Suter, T., Steger, G., et al. (2015). Final efficacy results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer. Cancer Research. Baltimore: Faculdade de Medicina, Universidade de São Paulo. doi:10.1158/1538-7445.SABCS14-PD2-2
NLM
Bell R, Brown J, Parmar M, Toi M, Suter T, Steger G, Pivot X, Mackey J, Jackisch C, Dent R, Hall P, Mecke A, Morales L, Provencher L, Staroslawska E, Hegg R, Vanlemmens L, Kirsch A, Schneeweiss A, Masuda N, Overkamp F, Cameron D. Final efficacy results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer [Internet]. Cancer Research. 2015 ; 75[citado 2024 abr. 18 ] Available from: https://doi.org/10.1158/1538-7445.SABCS14-PD2-2
Vancouver
Bell R, Brown J, Parmar M, Toi M, Suter T, Steger G, Pivot X, Mackey J, Jackisch C, Dent R, Hall P, Mecke A, Morales L, Provencher L, Staroslawska E, Hegg R, Vanlemmens L, Kirsch A, Schneeweiss A, Masuda N, Overkamp F, Cameron D. Final efficacy results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer [Internet]. Cancer Research. 2015 ; 75[citado 2024 abr. 18 ] Available from: https://doi.org/10.1158/1538-7445.SABCS14-PD2-2
Trabalho de evento-resumo periodico
A phase 2 study of neoadjuvant goserelin and letrozole for premenopausal women with estrogen receptor positive HER2 negative stage 2 and 3 breast cancer (2015)
Mattar, Andre; Goncalves, Rodrigo; Ellis, Matthew J.; Hegg, Roberto
Source: Cancer Research. Conference titles: Annual CTRC-AACR San Antonio Breast Cancer Symposium. Unidade: FM
Subjects: TERAPIA DA REPOSIÇÃO HORMONAL, NEOPLASIAS MAMÁRIAS (ETIOLOGIA;PREVENÇÃO E CONTROLE), ANTINEOPLÁSICOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MATTAR, Andre et al. A phase 2 study of neoadjuvant goserelin and letrozole for premenopausal women with estrogen receptor positive HER2 negative stage 2 and 3 breast cancer. Cancer Research. Baltimore: Faculdade de Medicina, Universidade de São Paulo. Disponível em: https://doi.org/10.1158/1538-7445.SABCS14-OT2-1-02. Acesso em: 18 abr. 2024. , 2015
APA
Mattar, A., Goncalves, R., Ellis, M. J., & Hegg, R. (2015). A phase 2 study of neoadjuvant goserelin and letrozole for premenopausal women with estrogen receptor positive HER2 negative stage 2 and 3 breast cancer. Cancer Research. Baltimore: Faculdade de Medicina, Universidade de São Paulo. doi:10.1158/1538-7445.SABCS14-OT2-1-02
NLM
Mattar A, Goncalves R, Ellis MJ, Hegg R. A phase 2 study of neoadjuvant goserelin and letrozole for premenopausal women with estrogen receptor positive HER2 negative stage 2 and 3 breast cancer [Internet]. Cancer Research. 2015 ; 75[citado 2024 abr. 18 ] Available from: https://doi.org/10.1158/1538-7445.SABCS14-OT2-1-02
Vancouver
Mattar A, Goncalves R, Ellis MJ, Hegg R. A phase 2 study of neoadjuvant goserelin and letrozole for premenopausal women with estrogen receptor positive HER2 negative stage 2 and 3 breast cancer [Internet]. Cancer Research. 2015 ; 75[citado 2024 abr. 18 ] Available from: https://doi.org/10.1158/1538-7445.SABCS14-OT2-1-02

USP Schools

ReP

Filtros

Departament

Authors

USP affiliated authors

Subjects